Display options
Cite
Ghanem NM, Farouk F, George RF, et al. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity. Bioorg Chem. 2018;80:565-576doi: 10.1016/j.bioorg.2018.07.006.
Ghanem, N. M., Farouk, F., George, R. F., Abbas, S. E. S., & El-Badry, O. M. (2018). Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity. Bioorganic chemistry, 80565-576. https://doi.org/10.1016/j.bioorg.2018.07.006
Ghanem, Nada M, et al. "Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity." Bioorganic chemistry vol. 80 (2018): 565-576. doi: https://doi.org/10.1016/j.bioorg.2018.07.006
Ghanem NM, Farouk F, George RF, Abbas SES, El-Badry OM. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity. Bioorg Chem. 2018 Oct;80:565-576. doi: 10.1016/j.bioorg.2018.07.006. Epub 2018 Jul 06. PMID: 30025343.
Copy Download .nbib Format: NLM
Share it on

Bioorg Chem. 2018 Oct;80:565-576. doi: 10.1016/j.bioorg.2018.07.006. Epub 2018 Jul 06.

Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.

Bioorganic chemistry

Nada M Ghanem, Faten Farouk, Riham F George, Safinaz E S Abbas, Ossama M El-Badry

Affiliations

  1. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
  2. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
  3. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. Electronic address: [email protected].

PMID: 30025343 DOI: 10.1016/j.bioorg.2018.07.006

Abstract

New imidazo[4,5-b]pyridine derivatives were designed, synthesized and screened for their anticancer activity against breast (MCF-7) and colon (HCT116) cancer cell lines. Nine compounds (I, II, IIIa, IIIb, IV, VI, VIIa, VIII, IX) showed significant activity against MCF-7, while six compounds (I, VIIc, VIIe, VIIf, VIII, IX) elicited a remarkable activity against HCT116. Compounds showing significant anticancer activity revealed remarkable CDK9 inhibitory potential (IC

Copyright © 2018 Elsevier Inc. All rights reserved.

Keywords: Anticancer; CDK9; HCT116; Imidazo[4,5-b]pyridines; MCF-7

Substances

MeSH terms

Publication Types